Tag: GlobeNewswire

BONDUELLE
Partnership limited by shares with a capital of 57 102 699,50 euros
Head office : La Woestyne – 59173 Renescure – France
447 250 044 RCS Dunkerque

2025-2026 Annual results
(July 1, 2025 – June 30, 2026)

The Bonduelle Group demonstrates its resilience, ending fiscal year 2025-2026 with stable sales and profitability

Message from Xavier Unkovic – Chief Executive Officer

Transforming ourselves to sustainably strengthen our performance

The past fiscal year unfolded in a particularly challenging environment, marked by the accumulation of major external shocks. In particular, our group faced the impact of unregulated imports of Chinese sweet corn, which put pressure on both volumes and selling prices, rising energy costs driven by international geopolitical tensions, and an exceptional heatwave that significantly affected agricultural yields for the 2026 harvest.

These adverse factors slowed the improvement of our profitability trajectory and temporarily weighed the delivery of our roadmap. However, they do not call into question the fundamentals of our strategy. On the contrary, they underscore the need to continue, with determination, the transformation already underway in order to strengthen the resilience of our business model in an environment that has remained particularly volatile over the past two years.

We are therefore continuing to execute our Transform to Win program to equip the company with the means to grow and enhance its competitiveness.
We have focused our resources on value-creating activities, brands and categories, evolved our portfolio through innovation to meet changing consumer expectations, and improved our operational efficiency.

This year’s financial performance does not yet fully reflect the potential of this transformation. However, the foundations are now firmly in place, our priorities are clear, and the first signs of progress are already visible.

In an environment that remains uncertain, we are fully committed to accelerating Bonduelle’s transformation. The group’s B Corp certification in January 2026 demonstrates our commitment to delivering profitable and sustainable growth, creating long-term value for all our stakeholders.

*****

On October 2, 2026, the Supervisory Board, under the chairmanship of Jean-Pierre Vannier, reviewed the statutory and consolidated financial statements for FY 2025-2026 as approved by the General Management and certified by the company’s statutory Auditors.

*****

Financial Performance

(in millions of euros)	2025-2026	2024-2025	Variation
Sales	2,186.2	2,203.8	-0.8%
Current Operating Income	79.6	83.8	-5.0%
Net income from continuing operations	16.2	-11.5	+27.7
Current operating cash flow (1)	98.9	71.4	+27.5

The Bonduelle Group’s sales for fiscal year 2025-2026 (ended June 30, 2026) amounted to 2,186.2 million euros, a variation of +0.4% on a like-for-like basis ⁽²⁾. After accounting for currency exchange fluctuations, sales recorded a slight decrease of 0.8% on reported figures.

Net income rose by 27.7 million euros despite a 5.0% decrease in current operating income on reported figures, while the current operating margin reached 3.6% on reported figures.

Improved working capital requirements, resulting from a substantial reduction in inventory levels and rigorous investment control, contributed to the growth in current operating cash flow ⁽¹⁾.

Business activity – Key figures

Activity by Geographical Region

Total consolidated sales (in millions of euros)	2025-2026	2024-2025	Variation at current exchange rates	Variation at constant exchange rates and scope
Europe Zone	1,372.1	1,354.5	1.3%	1.3%
Non-Europe Zone	814.0	849.3	-4.1%	-1.0%
Total	2,186.2	2,203.8	-0.8%	0.4%

Activity by Operating Segment

Total consolidated sales (in millions of euros)	2025-2026	2024-2025	Variation at current exchange rates	Variation at constant exchange rates and scope
Canned	1,119.9	1,070.5	+4.6%	+3.5%
Frozen	305.1	298.2	+2.3%	+2.0%
Fresh processed	761.2	835.1	-8.8%	-4.1%
Total	2,186.2	2,203.8	-0.8%	+0.4%

Europe Zone

The Europe Zone, which accounted for 62.8% of the business activity over the period, rose by +1.3% on both reported figures and a like-for-like basis ⁽²⁾.

In a sluggish market, the canned foods segment delivered growth of 1.5%. This performance was driven by the growth of branded sales, including canned products, particularly under the Cassegrain brand, as well as the gradual normalization of private-label volumes following the introduction of tariffs on Chinese sweet corn imports. The large-scale activation plan rolled out for the Bonduelle brand across Europe, featuring a new visual identity, a powerful communication campaign, and innovations designed to meet evolving consumer expectations, is beginning to deliver tangible results in several markets.

The frozen products segment recorded growth of 2.1%, driven by the gradual ramp-up of Bonduelle branded innovations in the retail channel, in line with the strategic evolution of our portfolio, as well as by increased activity in the food service activity.

The fresh prepared salads business declined by 0.4%, impacted by competitive pressure and delisting losses. However, the Quarter 4 marked a gradual recovery in activity (+4.4%), supported by favorable weather conditions to the consumption of fresh prepared products and by the launch of new branded products in France and Italy.

Non-Europe Zone

The Non-Europe Zone, representing 37.2% of the business activity over FY 2025-2026, decline by 1.0% on like-to-like basis ⁽²⁾ (-4.1% on reported figures).

After a year of growth in 2024-2025, North American operations declined by 5.6% on a like-for-like basis ⁽²⁾ (-12.4% on reported figures) over the full fiscal year. Market conditions remained challenging, with inflation and the impact of several agricultural crises putting significant pressure on raw material availability, which weighed heavily on performance despite the strong momentum on our innovations and the recovery in the foodservice channel (+9.4%).

The Eurasia, Export and Mercosur region recorded growth of 8.7% on a like-for-like basis ⁽²⁾ (+13.6% on reported figures). This performance was driven by the growth of our brands and brand activation initiatives in a dynamic market environment, as well as by the success of several product innovations.

Current Operating Income

(in millions of euros)	2025-2026	2024-2025	Variation at current exchange rates	Variation at constant exchange rates and scope
Sales	2,186.2	2,203.8	-0.8%	+0.4%
Current operating income	79.6	83.8	-5.0%	-10.5%
Current operating margin rate	3.6%	3.8%	-16 bps	-41 bps

For fiscal year 2025-2026, the Bonduelle Group reported a current operating income of 79.6 million euros at current exchange rates and 75.0 million euros at constant exchange rates, compared with 83.8 million euros in the previous fiscal year. Current operating margin stood at 3.6% on reported figures, representing a decline of 16 basis points at current exchange rates, and 3.4% on a like-for-like basis ⁽²⁾, representing a decline of 41 basis points compared with the previous fiscal year.

This decrease in current operating profitability reflects the following developments and contributions:

• In Europe, despite sales growth driven in particular by higher value-added meal solutions, profitability declined compared with the previous fiscal year. This was mainly due to increased pricing pressure from private-label products, which drove prices downward, as well as elevated inventory levels in certain categories, particularly sweet corn;
• Outside Europe, current operating profitability improved slightly. This performance was primarily driven by the strong results achieved in Eurasia, where prices increase implemented in an inflationary environment helped support margins while preserving market positions. By contrast, Bonduelle Americas’ profitability remained broadly stable, impacted by several agricultural crises and less favorable market conditions;
• Operational performance improvement initiatives and overhead optimization programs continued to deliver benefits across the group. However, these gains were offset by the negative impact of underutilized industrial capacity, resulting from proactive inventory reduction measures.

Consolidated net income

As of June 30, 2026, in an uncertain economic environment that weighed on the pace of the group’s transformation plan, challenges in the North American fresh ready-to-eat business led to the recognition of a 35 million euros impairment charge on Bonduelle Americas’ goodwill. Combined with logistics optimization costs in the United States and restructuring and reorganization expenses, these items brought non-recurring charges for the period of -47.3 million euros. As a result, reported operating income amounted to 32.3 million euros compared with 73.0 million euros a year earlier.

Financial results improved to -29.2 million euros, compared with -35.1 million euros at the close of the previous fiscal year. Interest expense recorded during the year decreased significantly to -28.8 million euros, primarily driven by an improvement in the group’s financing cost (3.15% from 3.81%). Foreign exchange gains and losses were neutral during this period, compared with a 2.0 million euros loss in the prior year.

Income tax expense amounted to -24.4 million euros, compared with -20.1 million euros in the previous fiscal year.

Share of profit from equity-accounted investments contributed to 4.3 million euros, primarily reflecting Bonduelle’s share of earnings from its investment in Nortera Foods, which is accounted for using the equity method.

After taking into account net financial expense, income tax expense and the share of profit from equity-accounted investments, Bonduelle Group’s net income from continuing operations for fiscal year 2025-2026 amounted to a loss of 16.9 million euros, compared with a profit of 19.7 million euros in the previous fiscal year.

In accordance with IFRS 5, the contribution from businesses that have been sold, are held for sale or have been discontinued is reported under “Net income from discontinued operations”. Accordingly, items recorded under this heading for the fiscal year amounted to 33.1 million euros. These mainly include the capital gain arising from the disposal of the packaged salad business in France, as well as the annual result of BF Agricola in Spain, whose operations were discontinued during the year.

Including net income from discontinued operations, Bonduelle Group’s consolidated net income for fiscal year 2025-2026 amounted to 16.2 million euros, compared with the loss of 11.5 million euros in the previous fiscal year and the loss of 111 million euros two years earlier.

Financial situation

	June 30, 2024 reported	June 30, 2025 reported	June 30, 2026 reported
Net debt (in millions of euros)	561.9	571.2	577.4
Gearing (3)	0.88	0.94	0.92
Leverage ratio (4)	3.57	3.38	3.58

Net debt, after taking into account IFRS 5 standards, amounted to 577.4 million euros (compared with 571.2 million euros the previous fiscal year) and the leverage ratio ⁽⁴⁾ stood at 3.58 compared to 3.38 for the previous fiscal year.  

Other significant information

Sale of the packaged salad business in France

In accordance with its “Transform to win” transformation plan, the group completed the sale of its packaged salad business in France to the LSDH group on July 17, 2025, after several years of declining results in this segment.

Annual General Meeting on December 3, 2026 – Dividend

During the Annual General Meeting, to be held on December 3, 2026, a dividend of 0.25 euro per share will be proposed.

Outlook

In a context that continues to be marked by significant agricultural and geopolitical uncertainties, the Bonduelle Group will focus its efforts on maintaining profitability and strengthening its financial fundamentals, particularly through improved cash flow generation and further debt reduction.

⁽¹⁾ current operating income plus depreciation and the change in working capital requirements, and after deduction of investments
⁽²⁾ at constant currency exchange rate and scope of consolidation basis. Net sales in foreign currency over the given period are translated into the rate of exchange for the comparable period. The impact of business acquisitions (or gain of control) and divestments is restated as follows:

• For businesses acquired (or gain of control) during the current period, net sales generated since the acquisition date are excluded from the organic growth calculation;
• For businesses acquired (or gain of control) during the prior fiscal year, net sales generated during the current period up until the first anniversary date of the acquisition are excluded;
• For businesses divested (or loss of control) during the prior fiscal year, net sales generated in the comparative period of the prior fiscal year until the divestment date are excluded;
• For businesses divested (or loss of control) during the current fiscal year, net sales generated in the period commencing 12 months before the divestment date up to the end of the comparative period of the prior fiscal year are excluded.

⁽³⁾ net financial debt / equity
⁽⁴⁾ net financial debt / recurring EBITDA

Alternative performance indicators: the group presents in its financial notices performance indicators not defined by accounting standards. The main performance indicators are detailed in the financial reports available on www.bonduelle.com

 

Next financial events:
                                                                                                                                                                                                                                                      
– Information meeting:                                                                                 October 5, 2026

– 2026-2027 1^st Quarter sales:                                                                    November 5, 2026 (after market closing)
– Annual General Meeting:                                                                           December 3, 2026
– 2026-2027 1^st Half Year Sales and Results:                                             February 25, 2027 (after market closing)

Find all annual results
And the schedule of financial publications on www.bonduelle.com

About the Bonduelle Group

The Bonduelle Group is, above all, a family story from the north of France that has lasted for 7 generations. Present in nearly 100 countries, we are proud of our iconic brands: Bonduelle, Cassegrain, and Globus. We collaborate with more than 2,000 passionate growers to offer you vegetables and pulses harvested at the peak of their flavor and nutrition.

Because we believe that every meal is an opportunity to make a difference, we are committed to inspire the transition toward a plant-rich diet, for the well-being of all and planet health. 100% B Corp certified since January 1, 2026, we are affirming our commitment to a more sustainable and responsible model.

For the 2025-2026 fiscal year, the company generated sales of 2.2 billion euros.  

Bonduelle is listed on Euronext Paris compartment B
Euronext indices: CAC MID & SMALL – CAC FOOD PRODUCERS – CAC ALL SHARES
Bonduelle is part of the Gaïa non-financial performance index and employees shareholder index (IAS)
Code ISIN: FR0000063935 – Code Reuters : BOND.PA – Code Bloomberg : BON FP

Attachment

• 2025-2026 Annual results

Sheen Dental and Hansen Incarnati join SDL as the Company plans to bring outsourced production to Sarasota

TAMPA, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) — Standard Dental Labs Inc. (OTCQB: TUTH) (“SDL” or the “Company”) today announced the acquisition, effective October 2, 2026, of substantially all of the operating assets of Dr. Tooth, LLC, the dental laboratory business also known as Sheen Dental Laboratory and Hansen Incarnati. The acquisition expands SDL’s customer base and advances its strategy of consolidating Florida dental laboratories around regional production facilities.

Based on current operating levels, management estimates that the acquired business adds just over $800,000 in annualized revenue. Combined with SDL’s previously announced annualized revenue estimate of approximately $822,000 for its existing operations, the acquisition brings the Company’s estimated annualized revenue base to more than $1.6 million, nearly double the prior estimate. These figures reflect management’s estimates of operating activity extended over 12 months and are not a forecast of revenue to be reported for calendar 2026.

SDL plans to move production for the acquired business to its Sarasota facility, bringing work currently outsourced to China into the Company’s Florida operations. Management believes domestic production can strengthen quality control and communication with dentists, help recover former customer relationships and increase utilization of the Sarasota facility. By adding volume to its existing production infrastructure, SDL expects the acquisition to improve the facility’s profitability as integration progresses.

Management, which will included the existing Dr. Tooth management team of Denis Thaxton and Gavin White, believes these changes create an opportunity to rebuild the acquired business to more than $1.1 million in annualized revenue. Achieving that objective will depend on retaining current accounts, recovering customers and successfully transitioning production.

“Our focus is to bring this work back to Florida and give dentists direct access to the people making their restorations,” said James D. Brooks, President and Chief Executive Officer of Standard Dental Labs Inc. “We are adding an established customer base to our Sarasota operation, where the additional production can improve the economics of the facility. We also see a clear opportunity to win back business by giving customers the domestic production and responsive service they want.”

The transaction was structured as an asset purchase with a combination of cash and SDL common stock, including performance conditions tied to retained customer revenue.

About Standard Dental Labs Inc

Standard Dental Labs Inc. is a Florida-focused dental laboratory company pursuing growth through acquisitions and investment in domestic production capabilities. SDL serves dental practices through its laboratory operations and is focused on digital workflows, quality and responsive service. Its common stock trades on the OTCQB under the symbol TUTH.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding anticipated revenue growth, future acquisitions, integration efforts, scalability, financing initiatives, operational synergies, and long-term shareholder value. Forward-looking statements generally can be identified by words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “will,” “may,” “continue,” and similar expressions.

These statements are based on current expectations, estimates, and assumptions that are subject to significant risks and uncertainties, many of which are beyond the Company’s control. Actual results may differ materially from those expressed or implied by such forward-looking statements due to a variety of factors, including integration risks, customer retention, operational performance, financing availability, regulatory considerations, market conditions, and other risks disclosed in the Company’s filings with the Securities and Exchange Commission and disclosures published through OTC Markets.

The Company’s Regulation A offering statement referenced herein does not constitute an offer to sell or the solicitation of an offer to buy securities except pursuant to the qualified offering circular. Any investment should be made only after careful review of the offering materials and risk factors contained therein.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. Standard Dental Labs Inc. undertakes no obligation to update or revise forward-looking statements except as required by law.

Investor and Media Contact

Standard Dental Labs Inc.
424 E Central Blvd, Suite 308, Orlando, FL 32801
Phone: (407) 789-1923
Email: info@sdl.care
Investors: https://sdl.care/investors

SOURCE: Standard Dental Labs Inc.

SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company’s lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting & Pre-Conference Programs taking place November 4 to 8, 2026, in Phoenix, Arizona. SITC plans to release further details for regular abstracts on November 3, 2026.

Presenting Author	Abstract Title	Presentation Details
Matthew Block, Department of Oncology, Mayo Clinic	A phase I/IIa trial of [212Pb]VMT01 MC1R-targeted alpha-particle mono- and combination-therapy with nivolumab in participants with previously treated unresectable or metastatic melanoma	Abstract Number: 571 Presentation type: Poster presentation Date: Friday, Nov. 6, 2026 Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6

About [²¹²Pb]VMT-01

Perspective designed [²¹²Pb]VMT01 to target and deliver ²¹²Pb to metastatic melanoma tumor sites expressing MC1R, a protein that can be overexpressed in metastatic melanoma tumors.¹ The Company is conducting a multi-center, open-label dose escalation, dose expansion study (clinicaltrials.gov identifier NCT05655312) in patients with histologically confirmed melanoma and MC1R-positive imaging scans.

Interim analysis with a data cut-off date of March 25, 2026 was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026. Highlights from the ASCO analysis included the following:

• Patients were heavily pre-treated prior to entering trial with a median of 4 prior lines of systemic therapy (including prior checkpoint inhibitors)
• One new response was observed early in the 3.0 mCi monotherapy cohort, in addition to a previously reported response, for a total of two responders out of seven treated patients
• Six patients (86%) experienced stable disease or partial response out of the seven patients in the 3.0 mCi monotherapy cohort; four patients completed all three treatments with 24 weeks or more of follow-up since their first treatment, and two remained on treatment and in study
• [²¹²Pb]VMT01 was well-tolerated with no dose limiting toxicities (DLTs), no discontinuations due to adverse events, and no Grade 4 or Grade 5 treatment emergent adverse events (TEAEs)
• Eight (30%) patients out of a total of 27 patients treated experienced Grade 3 TEAEs

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary ²²⁴Ra/²¹²Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s preclinical development plans and clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and development activities; economic and market conditions may worsen; regulatory agencies may issue decisions that negatively impact the Company’s product candidates and clinical development plans; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com

---

¹ Su DG, Djureinovic D, Schoenfeld D, et al. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precis Oncol. 2024;8:e2300702. doi:10.1200/PO.23.00702.

NACON ANNOUNCES THE REVOLUTION 5 UNLIMITED, THE NEW HIGH-END CONTROLLER FOR PLAYSTATION®5 CONSOLES AND PC*

NACON today unveils the new REVOLUTION 5 UNLIMITED® controller, an officially licensed PlayStation 5 asymmetric controller equipped with a built-in control screen, a charging dock, and TMR magnetic technology.

Lesquin (France), October 2 – NACON, a leading video game publisher and designer of premium gaming accessories, is pleased to announce the upcoming release of the Revolution 5 Unlimited (R5U), its new premium controller that is officially licensed for PS5® consoles. Building on the success of its Revolution range among competitive and professional players since 2016, the brand is reaching a new technological milestone today by unveiling its most advanced accessory yet for PlayStation 5 consoles and PC*. It is available for pre-order starting today on nacongaming.com.

Watch the Revolution 5 Unlimited announcement trailer https://youtu.be/bK1WUCRrhyo

The Revolution 5 Unlimited is the culmination of years of research and continuous feedback from the esports community and the most demanding competitive players. This new high-end asymmetric controller, officially licensed for PlayStation 5 consoles, includes major hardware innovations.
The built-in control screen – a world-first for an officially licensed PS5 controller – offers instant adjustments without ever leaving the game. Players can adjust audio mixing, joystick sensitivity, shortcut mapping, and manage controller system settings on the fly.
At the heart of the controller, TMR (Tunneling Magnetoresistance) magnetic technology makes its debut in NACON’s lineup, to significantly improve reliability, while delivering surgical precision and reduced power consumption.

Built for competition, the R5U features micro-switch action buttons, Trigger Blockers with instant trigger technology to switch from an analog pull to an ultra-short click, as well as multiple remappable shortcut buttons. It also boasts advanced software features, such as the Shooter Pro Mode, which completely removes joystick dead zones to deliver enhanced responsiveness, precision, and performance.

The controller comes with comprehensive accessories, a storage case and a dedicated charging dock – for the first time at NACON for an officially licensed PS5 controller – allowing users to charge and connect their gear in one convenient place.

Designed to be highly versatile, it also includes:
– Triple connectivity compatible with PS5® console, PC*, and Android Smart TVs, supported by a dedicated mobile app (iOS/Android) for fine-tuning advanced settings.
– A dedicated PC mode offering ultra-low 1ms latency and advanced features via the mobile app (such as mapping shortcut keys, configuring gyroscopic controls, etc.).

“With the Revolution 5 Unlimited, NACON demonstrates its ability to set new standards in the competitive gaming peripherals segment. By combining a built-in control screen and TMR technology on an officially licensed PlayStation asymmetric controller, we are giving competitive and demanding players a state-of-the-art instrument, backed by years of expertise within the Group,” says Yannick Allaert, Director of the Accessories Division at NACON.

The Revolution 5 Unlimited (R5U) is available for pre-order starting today at a suggested retail price of €199.99 / $229.99 / £179.99 on nacongaming.com.

***

About NACON
NACON is a BIGBEN Group company founded in 2019 to optimize its strong synergies in the video game market. By bringing together its development studios, AA game publishing, and the design and distribution of premium gaming peripherals, NACON focuses 40 years of expertise on serving gamers. This new unified hub strengthens NACON’s position in the market and enables it to innovate by creating unique competitive advantages. https://corporate.nacongaming.com/

“PlayStation Family Mark”, “PlayStation”, “PS5”, and “PlayStation Shapes” are registered trademarks or trademarks of Sony Interactive Entertainment, Inc. All rights reserved. All other trademarks are the property of their respective owners. Manufactured and distributed under license by Sony Interactive Entertainment and its affiliates.
*PC compatibility not tested or endorsed by Sony Interactive Entertainment.

Attachment

• PR_Annonce_Revolution_5_U_FINAL_EN

Ivry-sur-Seine – France, October 2^nd, 2026

TOTAL NUMBER OF SHARES
AND VOTING RIGHTS

Statement in compliance with article L. 233-8 II of the French commercial code and article 223- 16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des marchés financiers)

Stock Market	Euronext Paris
ISIN Code	FR0011476928

Date	Total number of shares composing the share capital of the company	Total number of gross voting rights	Total number of net voting rights (*)
September 30, 2026	29,682,146	29,682,146	29,369,800

(*) Net = After deduction of the shares deprived of voting right

In accordance with Article 9 of the Company’s Articles of Association, any physical or legal person, acting alone or in concert, who comes to hold, or ceases to hold, directly or indirectly, a percentage of the company’s capital or voting rights equal to or greater than 3% or any multiple of 1% above 3%, is required to inform the company by registered letter with return receipt requested within the time limit provided for in Article R. 233-1 of the French Commercial Code (i.e., as of today, at the latest before the close of trading on the fourth trading day following the day on which the shareholding threshold is crossed).

Under the terms of the twentieth resolution of the General Meeting of 29 May 2015, it was decided not to grant any double voting rights as instituted by law 2014-384 of 29 March 2014.

CONTACT

ANALYSTS / INVESTORS                                        investisseurs@fnacdarty.com

Attachment

• Number of shares and voting rights as of September 30, 2026

French public limited company (société anonyme)
with a share capital of €1,470,559,215.00
Registered office : 1973, boulevard de la Défense
92000 Nanterre – France
552 037 806 RCS Nanterre
www.vinci.com

DISCLOSURE
OF THE NUMBER OF SHARES FORMING THE CAPITAL
AND OF THE TOTAL NUMBER OF VOTING RIGHTS
AS OF 30 SEPTEMBER 2026

Total number of shares	588,223,686
Theoretical number of voting rights (including treasury stock)	588,223,686
Number of voting rights (excluding treasury stock)	551,548,982

This disclosure is on VINCI website www.vinci.com
(section: Finance/Investors/Regulatory information/7. Monthly information concerning the total number of voting rights and shares that make up the company’s capital)

Attachment

• 2026 09 30 ddv English version

• Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and improvements in disease activity (28.8%; CLASI-70) than at week 24 (19.0% and 21.7%, respectively)
• Rapid onset: Participants that switched from placebo to litifilimab experienced improvements in skin disease activity in as early as four weeks — consistent with results seen in participants who started on litifilimab reported earlier this year
• Consistent safety: Litifilimab’s safety profile remained consistent with previous studies, with no new safety signals identified
• Results from the Phase 3 part of AMETHYST are expected in the first half of 2027; in January 2026 the FDA granted Breakthrough Therapy Designation to litifilimab in CLE

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated results, presented at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria, represent the longest dataset reported for litifilimab in CLE and further support its potential to achieve rapid and durable improvements in skin disease activity. In the study, participants treated with litifilimab in the double-blind, placebo-controlled period showed continued clinical improvements in skin disease activity through Week 52. Notably, participants who switched from placebo to litifilimab treatment at Week 24 experienced a rapid onset of treatment effect as early as four weeks.  

“Access to 52-week data is critical when evaluating a treatment for a lifelong, chronic disease like cutaneous lupus erythematosus, which can cause permanent scarring and disfigurement that many patients will carry with them forever. That is why achieving clear or almost clear skin, which is rarely seen in CLE, is a truly transformative treatment goal for this disease,” said Joseph F Merola, MD, MMSc, dermatologist, rheumatologist and President of the Rheumatologic Dermatology Society, Lupus Foundation Medical and Scientific Board. “It is highly encouraging to see continued improvement in skin clearance with litifilimab treatment – with over a quarter of participants reaching clear or almost clear skin – and data supporting litifilimab’s long-term safety profile.”

Litifilimab is being evaluated as a potential once-monthly, first-in-class treatment designed to reduce inflammation at its source by selectively targeting blood dendritic cell antigen 2 (BDCA2) receptors on plasmacytoid dendritic cells (pDCs), which play a central role early in the inflammatory process in CLE. In January 2026, litifilimab was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of CLE. 

The Phase 2 portion of the ongoing Phase 2/3 AMETHYST study evaluated 93 adults with active skin symptoms for whom standard antimalarial medications were not effective or not tolerable. Over the course of a full year, the study tracked key measures of skin redness, scaling and disease activity to assess how well litifilimab helped participants achieve healthier skin. By Week 52, more than a quarter (27.2%) of participants who received litifilimab from the beginning of the study achieved the clinical endpoint of clear or almost clear skin, as measured by a Cutaneous Lupus Activity Investigators’ Global Assessment Revised (CLA-IGA-R) erythema score of 0 or 1, up from 19.0% at Week 24. Similar improvements were seen on the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity-70 (CLASI-70) measurement with 28.8% of participants receiving litifilimab from the beginning of the study achieving a 70% or greater reduction in CLASI A at Week 52, compared to 21.7% at Week 24. For participants who started the study on placebo and transitioned to litifilimab halfway through the study, the onset of benefit was rapid – as early as four weeks – when skin symptoms began to improve. By Week 52, approximately one in three (33.7%) of these crossover participants reported clear or almost clear skin.

“Living with cutaneous lupus erythematosus carries a heavy physical toll, including dyspigmentation, pain, and scarring, which can be associated with comorbidities like depression and anxiety that can have a profound impact on daily life. These 52-week data reinforce litifilimab’s potential to deliver rapid improvement and demonstrate its durable skin clearance effects,” said Daniel Quirk, M.D., Chief Medical Officer at Biogen. “We are encouraged by these results that build on findings in earlier studies as we anticipate the upcoming Phase 3 study results that reflect our commitment to advancing targeted therapies for serious autoimmune conditions.”

Over the course of the 52-week treatment period, litifilimab was generally well tolerated with a safety profile consistent with previously reported Phase 2 studies and no new safety signals identified. The majority of adverse events (AEs) reported were mild or moderate in severity, and serious AEs occurred in 3.4% (3/88) of participants during the extended treatment period. The most common AEs (≥5% during the extended treatment period) were nasopharyngitis, influenza and arthralgia.  

“People living with cutaneous lupus erythematosus face debilitating symptoms, including scarring, hair loss, and extreme sensitivity to light, yet they have long relied on treatments not specifically developed or studied for CLE,” said Albert T Roy, President and CEO of the Lupus Research Alliance. “The new data on litifilimab are encouraging because they point to the potential for both rapid symptom relief and durable improvement for people living with this condition. We look forward to seeing additional data from the Phase 3 study.”

About AMETHYST

AMETHYST is a two-part, Phase 2/3 multicenter, double-blind, placebo controlled, randomized study to evaluate the efficacy and safety of litifilimab compared to placebo. The study aims to assess the efficacy of litifilimab in participants with active subacute cutaneous lupus erythematosus (SCLE) and/or chronic cutaneous lupus erythematosus (CCLE) who are refractory or intolerant to antimalarial therapy. The Phase 2 and Phase 3 parts of the study are each 52 weeks in duration. Participants will be randomized to receive subcutaneous treatment with litifilimab or placebo every four weeks for 20 weeks with an additional dose at Week 2. All participants will receive litifilimab during the 28-week extended treatment period from Weeks 24 to 48. The Phase 3 part of the AMETHYST study remains blinded and is expected to read out in the first half of 2027. More information on the AMETHYST study (NCT05531565) is available at clinicaltrials.gov.

About Litifilimab (BIIB059)

Litifilimab (known as BIIB059) is an investigational first-in-class monoclonal antibody that is the first potential treatment developed by Biogen for lupus and is being evaluated in patients with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Its targeted mechanism of action acts early in the disease pathway to address the immune dysregulation that drives lupus. Litifilimab selectively targets BDCA2 receptors on plasmacytoid dendritic cells (pDCs) to reduce inflammation. Biogen developed litifilimab over two decades as part of a dedicated lupus discovery and development program.

Litifilimab is an investigational therapeutic candidate that has not yet been approved by any regulatory authority, and its safety and effectiveness have not been established.

Positive results from the CLE portion of the two-part Phase 2 LILAC study were previously published in The New England Journal of Medicine (NEJM) showing litifilimab met the study’s primary endpoint by demonstrating superior efficacy to placebo in reducing skin disease activity. In LILAC, litifilimab was generally well tolerated. The AMETHYST (NCT05531565) Phase 3 trial of litifilimab in CLE is currently ongoing.

About Cutaneous Lupus Erythematosus (CLE)

CLE, a type of lupus, is a serious autoimmune skin disease that impacts the daily lives of patients, including their emotional and mental health. It can lead to disfigurement in the form of hair loss, permanent scarring and abnormal skin color. In CLE, the immune system attacks healthy skin, causing rashes, pain, itching and sensitivity to sunlight. Currently, there are no approved targeted therapies for CLE and the last drug was approved in the 1950s.

About Biogen

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor

This news release contains forward-looking statements relating to, among others, the potential clinical effects of litifilimab; the potential of litifilimab to make a clinically meaningful improvement for patients living with cutaneous lupus erythematosus (CLE); the potential benefits, safety and efficacy of litifilimab; potential regulatory discussions, submissions and approvals and the timing thereof; the expected timing of trial results; the anticipation of Phase 3 trial results; the potential of Biogen’s commercial business and pipeline programs, including litifilimab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Digital Media Disclosure
From time to time we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SECÕs Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and this social media channel in addition to our press releases, SEC filings, public conference calls and webcasts, as the information posted on them could be material to investors.

MEDIA CONTACT:  Biogen  Madeleine Shin  +1-781-464-3260  public.affairs@biogen.com

INVESTOR CONTACT:  Biogen  Tim Power  +1 781 464 2442  IR@biogen.com

Company announcement
No. 61/2026

2 October 2026

Major shareholder announcement

Netcompany Group A/S (“Netcompany”) hereby announces the following notification received pursuant to section 38, 39, and 40 of the Danish Capital Markets Act from The Goldman Sachs Group, Inc., regarding their direct and indirect holdings and voting rights in Netcompany.

On 1 October 2026, The Goldman Sachs Group, Inc. informed Netcompany, that The Goldman Sachs Group, Inc. on 25 September 2026 directly and indirectly controlled 2,618,706 voting rights corresponding to 5.70% of the total voting rights in the Company. Their direct and indirect voting rights at the previous announcement were 3.47%.

This announcement is in accordance with section 30 of the Danish Capital Markets Act.

For further information, please see the attached notification form.

Additional information
For additional information, please contact:

Netcompany Group A/S
Thomas Johansen, CFO, + 45 51 19 32 24
Frederikke Linde, Head of IR, +45 60 62 60 87

Attachments

• 61. Netcompany – Major shareholder announcement – GS
• 61. Notification GS

MT Højgaard Holding’s business unit Enemærke & Petersen has been awarded the order for an extensive refurbishment of the Taastrupgaard housing complex in Taastrup. The project will be carried out under a general contract for the housing association AKB Taastrup, which is managed by KAB.

The final contract is expected to be signed on 15 October, following expiration of the standstill period, and will be conditional upon obtaining schedule B approval from Høje-Taastrup Municipality. The contract covers phase 2 of the area’s master plan as well as an option for phase 3, which is expected to be contracted during 2028-29. Combined, the two phases involve work valued at DKK 665 million.

The refurbishment follows the “Fremtidens Taastrupgaard” master plan, which is supported by the Danish Building Fund. The master plan aims to significantly improve the quality of the neighborhood and the homes, while meeting the requirements of the Danish Parliament’s “Parallel Society Package” regarding the creation of mixed urban and residential areas with a wider range of services. The first phase of the master plan has already been completed; phases 2 and 3 entail a comprehensive refurbishment of 19 residential blocks comprising a total of 522 homes, along with landscaping and paving work.

As part of the refurbishment, two blocks will be demolished and 102 homes abolished, while several of the remaining homes will be converted into new housing types such as youth housing, accessible housing, and “drive-in” housing, and some homes will be merged. The facades of the blocks will be replaced or retrofitted with additional insulation, and new heating and ventilation systems, electrical installations, balconies, floors, and kitchens will be installed.

Work will commence in the first quarter of 2027 and be completed in the first quarter of 2030. Phase 2 involves 301 housing units, which will be reduced to 214. Phase 3 involves 221 units, which will be reduced to 183.

“We look forward to collaborating with AKB Taastrup, KAB, and the developer’s advisers to future-proof Taastrupgaard in one joint project team focused on progress, quality, and handover by block to minimise inconvenience for residents. We have a solid plan that we look forward to realising in close dialogue with the residents and their representatives,” says Kim Thinggaard, CEO of Enemærke & Petersen.

The contract has no impact on MT Højgaard Holding’s expectations for 2026, but it confirms Enemærke & Petersen’s market-leading position in the refurbishment and transformation of social housing, among other things through multi-year construction partnerships with KAB and Civica. Enemærke & Petersen is currently engaged in more than 25 housing refurbishment projects.

Further information:
CEO Rasmus Untidt and CFO Dennis Nørgaard can be contacted on telephone +45 31 21 68 72.

Attachment

• MTHH_Investor news 2Oct26

ANNOUNCEMENT NO. 316
2 October 2026

ChemoMetec A/S has completed the share buyback programme announced in company announcement no. 309 dated 15 May 2026. The programme provided for the repurchase of up to 500,000 shares for a total consideration of up to DKK 100 million.

Under the programme, ChemoMetec A/S repurchased a total of 239,950 shares for a total consideration of DKK 99,998,735.

Following completion of the programme, ChemoMetec A/S holds a total of 239,950 treasury shares, corresponding to 1.38% of the company’s share capital.

Additional Information

Martin Helbo Behrens, CEO
Tel.: (+45) 81 10 06 80 

Phillip Massie Price, CFO
Tel.: (+45) 81 10 06 80 

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.